Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT ON THE PASSING OF U.S. FDA ON-SITE INSPECTION BY PHARMARON SHAOXING, A WHOLLY-OWNED SUBSIDIARY

This announcement is made by Pharmaron Beijing Co., Ltd. (the "**Company**" and together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

Pharmaron (Shaoxing) Pharmaceutical Co., Ltd. (康龍化成(紹興)藥業有限公司) ("**Pharmaron Shaoxing**"), a wholly-owned subsidiary of the Company, underwent a cGMP (Current Good Manufacturing Practices) PAI (Pre-approval Inspection) by the Food and Drug Administration of the United States of the America ("**U.S. FDA**") between May 29, 2025 and June 4, 2025. The inspection scope covered various GMP systems including the quality system, the materials management system, the production management system, the equipment and facilities system, the packaging and labelling system and the laboratory control system.

The Company has recently been informed that Pharmaron Shaoxing has received an establishment inspection report ("**EIR**") from the U.S. FDA. The EIR confirms that the production facilities of Pharmaron Shaoxing have successfully passed the on-site quality inspection conducted by the U.S. FDA. According to the EIR, Pharmaron Shaoxing complies with the U.S. cGMP pharmaceutical quality standards and has passed the U.S. FDA certification. This marks the first time that the Company's commercial API (active pharmaceutical ingredient) production facilities in Shaoxing have passed the U.S. FDA pre-approval inspection for innovative drugs. Following the successful U.S. FDA on-site inspection of the Company's API production facilities in Ningbo in April 2025, the Company's API manufacturing facilities in China have once again passed the U.S. FDA inspection. This signifies that the Company's quality system has aligned with international standards and is qualified to continuously supply commercial innovative drug APIs to the U.S. and global markets. Currently, four of the Company's commercial API production facilities in China, the U.K., and the U.S. have passed U.S. FDA inspections, providing global clients with commercial API production solutions for innovative drugs tailored to different markets.

Pharmaron remains committed to serving as a trusted, reliable, and accountable partner, dedicated to supporting its clients' success in the global pharmaceutical industry. The successful inspection reflects Pharmaron's ongoing commitment to adhering to stringent international quality standards and underscores the effectiveness of its quality management systems. This accomplishment is expected to have a positive and lasting impact on the Company's continued growth and expansion within the global contract development and manufacturing organization (CDMO) sector for innovative pharmaceuticals.

Due to the characteristics of the pharmaceutical industry, drug production and sales are subject to uncertainties arising from policies, market environment and medication demand. Shareholders and potential investors are advised to exercise caution and be aware of the risks involved.

By order of the Board
Pharmaron Beijing Co., Ltd.
Dr. Lou Boliang
Chairman

Beijing, the PRC
September 15, 2025

As at the date of this announcement, the board of directors of Company comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive directors; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive directors; Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive directors.